Listen to episode 00
Episode summary
This webinar examines why software bills of materials can trigger questions during FDA review. The hosts discuss missing components, unclear scope, and the importance of presenting an understandable software inventory rather than assuming that generating a list completes the task.
Key points
- Missing software components
- Clarifying SBOM scope
- Addressing reviewer questions about inventories